{{noteTA|G1 = ME}} {{Medical}} 
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 477002307
| IUPAC_name = (1''R'',3''S'',5''R'',6''R'',9''R'', 11''R'',15''S'',16''R'',17''R'',18''S'',19''E'',21''E'', 23''E'',25''E'',27''E'',29''E'',31''E'',33''R'',35''S'',36''R'',37''S'')- 33-[(3-amino- 3,6-dideoxy- β-<small>D</small>-mannopyranosyl)oxy]- 1,3,5,6,9,11,17,37-octahydroxy- 15,16,18-trimethyl- 13-oxo- 14,39-dioxabicyclo [33.3.1] nonatriaconta- 19,21,23,25,27,29,31-heptaene- 36-carboxylic acid
| image =
| image2 =Amphotericin_b.png

<!--Clinical data-->
| tradename = Fungizone
| Drugs.com = {{drugs.com|monograph|amphotericin_b}}
| pregnancy_US = B
| pregnancy_category =  
| legal_status = Rx-only
| routes_of_administration = 仅缓慢[[静脉注射|静脉注射]]

<!--Pharmacokinetic data-->
| bioavailability = 100% (IV)
| metabolism = 肾脏
| elimination_half-life = 第一阶段为24小时<br/> 第二阶段大约15天
| excretion = 数天的累积后40%通过尿液排泄<br/> 同时也有胆汁排泄

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 1397-89-3
| ATC_prefix = A01
| ATC_suffix = AB04
| ATC_supplemental =  {{ATC|A07|AA07}}, {{ATC|G01|AA03}}, {{ATC|J02|AA01}}
| PubChem = 14956
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00681
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10237579
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00203
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 2682
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 267345
| NIAID_ChemDB = 000096

<!--Chemical data-->
 | C=47 | H=73 | N=1 | O=17 
| molecular_weight = 923.49| smiles = O=C(O)[C@@H]3[C@@H](O)C[C@@]2(O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)C=CC=CC=CC=CC=CC=CC=C[C@H](O[C@@H]1O[C@H](C)[C@@H](O)[C@H](N)[C@@H]1O)C[C@@H]3O2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = APKFDSVGJQXUKY-INPOYWNPSA-N
}}

<!-- Definition and medical uses -->
'''兩性黴素B'''（{{lang-en|'''Amphotericin B'''}}，商品名：{{lang|en|'''Fungizone'''}}），是一款[[抗真菌藥|抗真菌藥]]，常見透過[[靜脈注射|靜脈注射]]方式給予藥物<ref name=AHFS2015>{{cite web|title = Amphotericin B|url = https://www.drugs.com/monograph/amphotericin-b.html|publisher = The American Society of Health-System Pharmacists|accessdate = January 1, 2015|archiveurl = https://web.archive.org/web/20150101143314/http://www.drugs.com/monograph/amphotericin-b.html|archivedate = 2015-01-01|dead-url = no}}</ref>。兩性黴素B可用來治療[[真菌病|真菌病]]與[[利什曼病|利什曼病]]<ref name=WHO2010>{{cite book | vauthors = ((World Health Organization)) |title=Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases|date=March 2010|publisher=World Health Organization|isbn=9789241209496|pages=55, 88, 186 | author-link = World Health Organization | location = Geneva | hdl=10665/44412 | hdl-access=free }}</ref>。能夠治療的真菌病為{{le|麴菌病|aspergillosis}}、[[芽生菌病|芽生菌病]]、[[念珠菌症|念珠菌症]]、{{le|球黴菌症|coccidioidomycosis}}及[[隱球菌病|隱球菌病]]等<ref name=WHO2010/>。針對特定感染症，給藥時可以併用[[氟胞嘧啶|氟胞嘧啶]]<ref name=WHO2008>{{cite book | title = WHO Model Formulary 2008 | year = 2009 | isbn = 9789241547659 | vauthors = ((World Health Organization)) | veditors = Stuart MC, Kouimtzi M, Hill SR | hdl = 10665/44053 | author-link = World Health Organization | publisher = World Health Organization |page=145 | hdl-access=free }}</ref>。<!--一種具有抑菌或[[殺菌|殺菌]]作用的抗[[黴菌|黴菌]]劑。<ref name="[1]">Kintzel PE & Smith GH: Practical guidelines for preparing and administering amphotericin B. Am J Hosp pharm. (1992) 49, 1156-1164</ref>對新生隱球菌、白色[[念珠菌症|念珠菌]]、組織胞漿菌、球孢子菌、釀母菌均具抑制作用。<ref>常用藥物手冊 中華書局(香港)有限公司 周自永 王世祥</ref>其所產生的藥效端視其於[[生物|生物]]體內所達到的藥物濃度而定。<ref name="[2]">S. H. Khoo, Jeanette Bond and David W. Denning: Administering amphotericin B-a practical approach (Review). Journal of Antimicrobial Chemotherapy (1994) 33, 203-213</ref>-->

<!-- Side effects -->
常見的副作用為用藥後[[頭痛|頭痛]]、[[發燒|發燒]]或發冷，引發[[腎功能衰竭|腎功能衰竭]]<ref name=AHFS2015/>；也可能出現過敏症狀，例如[[過敏性休克|過敏性休克]]。而其他嚴重的副作用包含[[低鉀血症|低鉀血症]]和[[心肌炎|心肌炎]]等。[[妊娠|懷孕]]女性使用兩性黴素B算是相對安全<ref name=AHFS2015/>。本品另有一種脂質配方，其副作用的風險比較低<ref name=AHFS2015/>。兩性黴素B為{{le|多烯類|polyene}}藥物，藥理機制為結合至真菌細胞膜特有之麥角固醇，干擾真菌的[[細胞膜|細胞膜]]<ref name=WHO2010/><ref name=AHFS2015/>。

<!-- History and culture -->
1955年，從{{le|多結鏈黴菌|Streptomyces nodosus}}中分離出了兩性黴素B，並在1958年時將其納為醫藥用途<ref name=Wal2012>{{cite book|last1=Walker|first1=S. R.|title=Trends and Changes in Drug Research and Development|date=2012|publisher=Springer Science & Business Media|isbn=9789400926592|page=109|url=https://books.google.com/books?id=FB_2CAAAQBAJ&pg=PA109|language=en|archiveurl=https://web.archive.org/web/20170910151826/https://books.google.com/books?id=FB_2CAAAQBAJ&pg=PA109|archivedate=2017-09-10|access-date=2020-07-20|dead-url=no}}</ref><ref name=Fis2006>{{cite book |last1=Fischer |first1=Jnos |last2=Ganellin |first2=C. Robin |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=477 |url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA477 |language=en |access-date=2020-07-20 |archive-date=2020-12-10 |archive-url=https://web.archive.org/web/20201210062318/https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA477 |dead-url=no }}</ref>。本品名列於[[世界衛生組織基本藥物標準清單|世界衛生組織基本藥物標準清單]]，認可為[[醫療系統|醫療系統]]中最為安全有效的藥物之一<ref name="WHO21st">{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 21st list 2019 | year = 2019 | hdl = 10665/325771 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO | hdl-access=free }}</ref>，並已有[[通用名藥物|學名藥]]問世<ref name=AHFS2015/>。2010年在[[發展中國家|發展中國家]]，一整套療程的藥價約在162到229美元之间<ref name=WHO2010/>。

== 藥理作用 ==
兩性黴素B在[[黴菌|黴菌]]的[[細胞膜|細胞膜]]內與脂醇（真菌上的胞漿膜甾醇）（Ergosterol）結合而造成[[細胞膜|細胞膜]]通透性的改變，導致真菌細胞內的成分，鉀離子及其他成份如氨基酸、蛋白質等洩漏到膜外，破壞真菌正常代謝及抑制生長<ref name="#1">常用藥物手冊 中華書局(香港)有限公司 周自永 王世祥</ref>，細胞產生裂解而造成[[黴菌|黴菌]]細胞死亡。由於細菌的細胞膜上並不含麥角甾醇，故此藥對細菌並無抑制和／或殺滅作用。而人和動物的細胞膜上，則以[[膽固醇|膽固醇]]為主要成份，膽固醇與兩性黴素B具有一定親和力，因此對人體會具一定毒性。<ref name="#1"/>

== 作用及適應 ==
兩性霉素B是一種Streptomyces nodosus菌株的抗黴菌多烯（polyene）[[抗生素|抗生素]]。<ref name="[1]">Kintzel PE & Smith GH: Practical guidelines for preparing and administering amphotericin B. Am J Hosp pharm. (1992) 49, 1156-1164</ref>受限於其作用原理，此藥僅對真菌有效，對於[[細菌|細菌]]、[[病毒|病毒]]與[[立克次氏體|立克次氏體]]則無效。此藥一般主要用於治療嚴重及具有致命危險的全身性[[黴菌|黴菌]]感染，如：
*[[曲霉病|曲霉病]]（Aspergillosis）
*[[隱球菌病|隱球菌病]]（''Cryptococcus neoformans''）
*[[芽生黴菌病|芽生黴菌病]]（Blastomycosis）
*全身性的[[念珠菌病|念珠菌病]]、[[球孢子菌病|球孢子菌病]]（Coccidioidomycosis）
*[[组织浆胞菌病|组织浆胞菌病]]（Histoplasmosis）
*[[白黴菌病|白黴菌病]]（Mucormycosis）
*[[孢子絲菌病|孢子絲菌病]]（Sporotrichosis）<ref name="[3]">Drutz DJ, Spickard A, Rogers DE et al.: Treatment of disseminated mycotic infection. Am J Med.(1968) 45, 405-418</ref><ref name="[4]">Littman ML, Horowitz PL, Swadey JG.: Coccidioidomycosis and its treatment with amphotericin B. Am J Med. (1958) 24, 568-592
</ref>

== 用法及細節 ==
*兩性黴素B因在胃腸道的口服吸收效果較差，一般在重症的[[黴菌|黴菌]]感染時病患較常以[[靜脈注射|靜脈注射]]的方式給藥。<ref name="[1]">Kintzel PE & Smith GH: Practical guidelines for preparing and administering amphotericin B. Am J Hosp pharm. (1992) 49, 1156-1164</ref><ref name="[2]">S. H. Khoo, Jeanette Bond and David W. Denning: Administering amphotericin B-a practical approach (Review). Journal of Antimicrobial Chemotherapy (1994) 33, 203-213</ref>
*[[靜脈|靜脈]]輸注給藥應以較緩慢的方式（2至6小時的時間）為之。受推薦的輸注濃度為0.1mg/ml。
*每日的最大劑量為1.5mg/kg，目前於成人建議的治療療程為4至12週，或以累積劑量達1至4克為治療目標。
*測試劑量大小一般則以1mg兩性黴素B加入20ml 5%[[葡萄糖|葡萄糖]]溶液以靜脈注射的方式給予（在20至30分鐘內打完），這期間應每隔30分鐘定期監控病人的生理跡象（如：體溫、心跳、[[血壓|血壓]]、呼吸），並持續2-4小時。<ref name="[1]">Kintzel PE & Smith GH: Practical guidelines for preparing and administering amphotericin B. Am J Hosp pharm. (1992) 49, 1156-1164</ref><ref name="[7]">Grasela TH,Goodwin SD, Walawander MK et al.: Prospective surveillance of intravenous amphotericin B use patterns. Pharmacotherapy (1990) 10, 341-348</ref>
*病人的心、腎功能良好且對兩性黴素B之測試劑量耐受良好，一般可由每日0.25 mg/kg的起始劑量開始治療。<ref name="[1]">Kintzel PE & Smith GH: Practical guidelines for preparing and administering amphotericin B. Am J Hosp pharm. (1992) 49, 1156-1164</ref><ref name="[2]">S. H. Khoo, Jeanette Bond and David W. Denning: Administering amphotericin B-a practical approach (Review). Journal of Antimicrobial Chemotherapy (1994) 33, 203-213</ref>
*而治療療程及劑量仍需考慮病人對兩性黴素B的耐受性，個體間差異性，亦需依照著患者臨床狀態加以調整（例如：所感染的部位、致病原與病人的心肝腎功能如何）。<ref name="[5]">Medoff G, Kobayashi GS.: Strategies in the treatment of systemic fungal infection. N Engl J Med.(1980) 302, 145-155</ref>

=== 注意事項 ===
*因兩性黴素B為具高度毒性的[[藥物|藥物]]，除非為罹患進行性及有致命性之[[黴菌|黴菌]]感染之病患，否則不應該用此藥來治療一般瑣細的黴菌感染。而[[靜脈注射|靜脈注射]]此藥時必須在醫護人員嚴格的監護下進行。<ref name="[1]">Kintzel PE & Smith GH: Practical guidelines for preparing and administering amphotericin B. Am J Hosp pharm. (1992) 49, 1156-1164</ref><ref name="[2]">S. H. Khoo, Jeanette Bond and David W. Denning: Administering amphotericin B-a practical approach (Review). Journal of Antimicrobial Chemotherapy (1994) 33, 203-213</ref><ref name="[5]">Medoff G, Kobayashi GS.: Strategies in the treatment of systemic fungal infection. N Engl J Med.(1980) 302, 145-155</ref><ref name="[6]">Meyer, R.D.: Current role of therapy with amphotericin B. Clinical Infectious Diseases. (1992) 14, Suppl. 1, S154-160</ref>
*兩性黴素B必須慎用於心、肝、腎功能不全的患者。<ref name="[5]">Medoff G, Kobayashi GS.: Strategies in the treatment of systemic fungal infection. N Engl J Med.(1980) 302, 145-155</ref>治療期間肝、腎功能的測定及定期的實驗室檢驗是絕對必要的。<ref name="[1]">Kintzel PE & Smith GH: Practical guidelines for preparing and administering amphotericin B. Am J Hosp pharm. (1992) 49, 1156-1164</ref><ref name="[2]">S. H. Khoo, Jeanette Bond and David W. Denning: Administering amphotericin B-a practical approach (Review). Journal of Antimicrobial Chemotherapy (1994) 33, 203-213</ref>兩性黴素B給予過量會造成[[心臟|心臟]]及呼吸停止。如懷疑劑量超量應立即停藥，並監控患者的臨床生命狀況，必要給予支持性療法。兩性黴素B與[[血漿蛋白|血漿蛋白]]結合率很高（大於90%），自[[腎臟|腎臟]]來排除變得很緩慢（超過幾週或數月），不易被[[透析|透析]]來進行排除，因此重新開始此藥治療（藥物中斷7天以上）以前，應該從最低劑量（一天0.25mg/kg）重新開始漸次的增加劑量。
*因此藥的刺激性大，須以緩慢靜脈注射的方式給藥，且應避免注射部位發生[[發炎|發炎]]及外溢情形，因為這些狀況常導致[[血管|血管]]栓塞與[[血管|血管]]性[[靜脈|靜脈]]炎的產生。<ref name="[1]">Kintzel PE & Smith GH: Practical guidelines for preparing and administering amphotericin B. Am J Hosp pharm. (1992) 49, 1156-1164</ref><ref name="[2]">S. H. Khoo, Jeanette Bond and David W. Denning: Administering amphotericin B-a practical approach (Review). Journal of Antimicrobial Chemotherapy (1994) 33, 203-213</ref>
*調配時應善用無菌調製技巧，須留意濃度是否正確及藥物保存事宜，一旦發現注射液內有藥品沉澱產生，即應停止施打並重新再配製該藥品。<ref name="[1]">Kintzel PE & Smith GH: Practical guidelines for preparing and administering amphotericin B. Am J Hosp pharm. (1992) 49, 1156-1164</ref><ref name="[2]">S. H. Khoo, Jeanette Bond and David W. Denning: Administering amphotericin B-a practical approach (Review). Journal of Antimicrobial Chemotherapy (1994) 33, 203-213</ref>

==藥物相互作用與注意事項==
此藥與多種藥物均有配伍禁忌，單獨使用為宜，勿隨意與其他藥物合用。硫酸丁胺卡那黴素、[[抗組織胺藥|抗組織胺類藥物]]、[[青黴素|青黴素]]、[[氯化鈣|氯化鈣]]、[[葡萄糖酸鈣|葡萄糖酸鈣]]、羧苄青黴素鈉、[[氯丙嗪|氯丙嗪]]、[[多巴胺|多巴胺]]、慶大黴素、卡那黴素、阿拉明、多黏菌素B、[[氯化鉀|氯化鉀]]、[[氯化鈉|氯化鈉]]、盬酸普魯卡因、[[鏈黴素|鏈黴素]]、[[四環素|四環素]]、[[維生素|維生素]]類等等，都不可與兩性霉素B合用。

不可用[[生理鹽水|生理鹽水]]稀釋，因為會產生沉澱。

靜滴時，藥劑需避光，否則可逐漸引起降效。為減少不良反應如發熱、靜脈炎等，可以同時靜滴[[氫化可的松|氫化可的松]]或[[地塞米松|地塞米松]]，也可在滴注前半小時給予消炎痛或抗組織胺藥。注意必需在用本藥前半小時給予[[抗組織胺藥|抗組織胺藥]]。

==参考文献==
{{reflist|2}}

==外部連結==
{{portal|药理学|醫學}}
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/amphotericin%20B | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Amphotericin B | accessdate = 2020-02-13 | archive-date = 2020-12-10 | archive-url = https://web.archive.org/web/20201210062341/https://druginfo.nlm.nih.gov/drugportal/name/amphotericin%20B | dead-url = no }}
* [http://www.medicines.org.uk/emc/medicine/1236 AmBisome Summaries of Product Characteristics (United Kingdom)]{{Wayback|url=http://www.medicines.org.uk/emc/medicine/1236 |date=20201120013634 }}
* [https://www.acs.org/content/acs/en/molecule-of-the-week/archive/a/amphotericin-b.html Amphotericin B]{{Wayback|url=https://www.acs.org/content/acs/en/molecule-of-the-week/archive/a/amphotericin-b.html |date=20201025000602 }}
* {{cite web | title=Amphotericin B Liposomal Injection | website=MedlinePlus | url=https://medlineplus.gov/druginfo/meds/a616018.html | accessdate=2020-02-13 | archive-date=2020-12-10 | archive-url=https://web.archive.org/web/20201210062339/https://medlineplus.gov/druginfo/meds/a616018.html | dead-url=no }}
* {{cite web | title=Amphotericin B Lipid Complex Injection | website=MedlinePlus | url=https://medlineplus.gov/druginfo/meds/a601132.html | accessdate=2020-02-13 | archive-date=2020-12-10 | archive-url=https://web.archive.org/web/20201210062356/https://medlineplus.gov/druginfo/meds/a601132.html | dead-url=no }}

{{Stomatological preparations}}
{{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}}
{{Antifungals}}
{{Excavata antiparasitics|state=autocollapse}}
{{Gynecological anti-infectives and antiseptics}}

[[Category:吉利德科學|Category:吉利德科學]]
[[Category:抗真菌藥物|Category:抗真菌藥物]]
[[Category:聚酮抗生素|Category:聚酮抗生素]]
[[Category:世界衛生組織基本藥物|Category:世界衛生組織基本藥物]]
[[Category:抗原蟲藥|Category:抗原蟲藥]]